Edgewise Therapeutics, Inc. Operating Lease, Expense
Edgewise Therapeutics, Inc. (EWTX) reported Operating Lease, Expense of $110.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-02-24
- Edgewise Therapeutics, Inc. operating lease, expense for the quarter ending 2021-12-31 was $44.00K, a 100.00% increase year-over-year.
- Edgewise Therapeutics, Inc. operating lease, expense for the quarter ending 2021-09-30 was $22.00K, a 0.00% change year-over-year.
- Edgewise Therapeutics, Inc. operating lease, expense for the quarter ending 2021-06-30 was $22.00K, a 29.41% increase year-over-year.
- Edgewise Therapeutics, Inc. operating lease, expense for the quarter ending 2021-03-31 was $22.00K.
- Edgewise Therapeutics, Inc. operating lease, expense for fiscal 2021 was $110.00K, a 42.86% increase from fiscal 2020.
- Edgewise Therapeutics, Inc. operating lease, expense for fiscal 2020 was $77.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $66.00K derived: sum of 2 quarters · filed 2022-02-24 | $88.00K derived: sum of 3 quarters · filed 2022-02-24 | $110.00K 10-K · filed 2022-02-24 |
| 2021-09-30 | $22.00K 10-Q · filed 2021-11-10 | $44.00K derived: sum of 2 quarters · filed 2021-11-10 | $66.00K 10-Q · filed 2021-11-10 | $88.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2021-06-30 | $22.00K 10-Q · filed 2021-08-09 | $44.00K 10-Q · filed 2021-08-09 | $66.00K derived: sum of 3 quarters · filed 2022-02-24 | $88.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2021-03-31 | $22.00K derived: 10-K 12 month − 3 quarters · filed 2022-02-24 | $44.00K derived: sum of 2 quarters · filed 2022-02-24 | $66.00K derived: sum of 3 quarters · filed 2022-02-24 | $83.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $44.00K derived: sum of 2 quarters · filed 2022-02-24 | $61.00K derived: sum of 3 quarters · filed 2022-02-24 | $77.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $22.00K 10-Q · filed 2021-11-10 | $39.00K derived: sum of 2 quarters · filed 2021-11-10 | $55.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $17.00K 10-Q · filed 2021-08-09 | $33.00K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |